4.05
Schlusskurs vom Vortag:
$4.08
Offen:
$4.19
24-Stunden-Volumen:
415.77K
Relative Volume:
2.73
Marktkapitalisierung:
$43.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.25M
KGV:
-2.2753
EPS:
-1.78
Netto-Cashflow:
$-17.87M
1W Leistung:
-1.58%
1M Leistung:
-9.09%
6M Leistung:
+12.81%
1J Leistung:
+21.26%
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
LTRN
Lantern Pharma Inc
|
4.05 | 44.06M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Will Lantern Pharma Inc. stock recover after recent dropTrend Reversal & Low Risk Entry Point Guides - newser.com
Lantern Pharma Inc. stock trendline breakdownWeekly Stock Analysis & Free Community Supported Trade Ideas - newser.com
Will Lantern Pharma Inc. stock maintain dividend yieldQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Is Lantern Pharma Inc. stock a buy before product launchesIPO Watch & Target Return Focused Stock Picks - newser.com
Is Lantern Pharma Inc. stock attractive for income investors2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
Using economic indicators to assess Lantern Pharma Inc. potentialMarket Sentiment Review & Comprehensive Market Scan Reports - newser.com
How to interpret RSI for Lantern Pharma Inc. stock2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):